Semaglutide Linked to Reduced Psychiatric Hospitalization Risk in Bipolar Disorder Study
A large Swedish study published in JAMA Psychiatry has found that semaglutide—the active ingredient in Ozempic and Wegovy—may offer unexpected mental health benefits for people with bipolar disorder.
Researchers analyzed data from nearly 15,000 individuals with bipolar disorder and found that those using semaglutide had a 21% lower risk of psychiatric hospitalization compared to non-users. The study drew on registry data spanning multiple years, making it one of the larger observational investigations into GLP-1 receptor agonists and psychiatric outcomes.
Possible Mechanisms
The researchers propose several biological pathways that might explain the association. Semaglutide is known to reduce systemic inflammation, which has been increasingly linked to mood disorders. Additionally, the drug acts on GLP-1 receptors in the brain, potentially influencing neural circuits involved in emotional regulation.
Important Caveats
The findings come with notable limitations. The study was observational, meaning it cannot establish causation—other factors may explain the reduced hospitalization rate. Additionally, other GLP-1 drugs did not show the same protective association, raising questions about whether the effect is specific to semaglutide's unique properties or the study's design.
The researchers caution that more randomized controlled trials are needed before any clinical recommendations can be made. Patients should not start or change medications based on these preliminary findings and should consult their healthcare providers for guidance.
This study adds to a growing body of research exploring whether GLP-1 receptor agonists might have applications beyond their approved uses for diabetes and weight management.